within Pharmacolibrary.Drugs.ATC.L;

model L01EL02
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.25,
    Cl             = 0.0022333333333333333,
    adminDuration  = 600,
    adminMass      = 100 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0347,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.013466666666666667,
    Tlag           = 10.86,            
    Vdp             = 0.06709999999999999,
    k12             = 307,
    k21             = 307
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L01EL02</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Acalabrutinib is a selective Bruton tyrosine kinase (BTK) inhibitor used for the treatment of B-cell malignancies, including mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL). It is approved for use in several countries including the USA and EU.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for adult patients with B-cell malignancies after oral administration under fasting conditions.</p><h4>References</h4><ol><li><p>Barf, T, et al., &amp; Kaptein, A (2017). Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency Profile. <i>The Journal of pharmacology and experimental therapeutics</i> 363(2) 240–252. DOI:<a href=&quot;https://doi.org/10.1124/jpet.117.242909&quot;>10.1124/jpet.117.242909</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/28882879/&quot;>https://pubmed.ncbi.nlm.nih.gov/28882879</a></p></li><li><p>Xu, Y, et al., &amp; Ware, JA (2022). Evaluation of the Pharmacokinetics and Safety of a Single Dose of Acalabrutinib in Subjects With Hepatic Impairment. <i>Journal of clinical pharmacology</i> 62(6) 812–822. DOI:<a href=&quot;https://doi.org/10.1002/jcph.2013&quot;>10.1002/jcph.2013</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34897701/&quot;>https://pubmed.ncbi.nlm.nih.gov/34897701</a></p></li><li><p>Roschewski, M, et al., &amp; Flinn, I (2023). Phase I Study of Acalabrutinib Plus Danvatirsen (AZD9150) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Including Circulating Tumor DNA Biomarker Assessment. <i>Clinical cancer research : an official journal of the American Association for Cancer Research</i> 29(17) 3301–3312. DOI:<a href=&quot;https://doi.org/10.1158/1078-0432.CCR-22-2483&quot;>10.1158/1078-0432.CCR-22-2483</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/37364001/&quot;>https://pubmed.ncbi.nlm.nih.gov/37364001</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L01EL02;
